PROVECTUS BIOPHARMS - PVCT STOCK NEWS

Provectus has announced new preclinical research published in The Journal of Antibiotics demonstrating that its pharmaceutical-grade rose bengal sodium (RBS) effectively inhibits the growth of colistin-resistant gram-negative (G-) bacteria and exhibits rapid-killing characteristics. Colistin is recognized as a last-resort treatment for severe bacterial infections and is classified by the WHO as critically important to human health. The research, led by Dr. Michio Kurosu at the University of Tennessee Health Science Center, shows that Provectus' RBS formulation (HP-RBf) has significant potential against these resistant pathogens. This reinforces the capability of RBS to contribute to combination therapies in treating infectious diseases, as stated by Dominic Rodrigues, Vice Chair of Provectus’ Board of Directors.

Provectus (OTCQB: PVCT) issued a letter to stockholders highlighting 2023 plans focused on maximizing long-term value. The company, a late-stage biotechnology firm, is advancing its lead molecule, rose bengal sodium (RBS), through multiple clinical trials targeting various cancers. Notably, Provectus aims to pursue intratumoral immunotherapy for rare in-transit melanoma, supported by clinical efficacy data. In 2022, the company made strategic advancements, including new research collaborations and received significant patent awards, further bolstering its drug development pipeline.

Provectus (OTCQB: PVCT) announced it will not pursue the reverse stock split and share reduction approved by stockholders by December 31, 2022. The Board of Directors concluded that undertaking these measures is not in the best interests of shareholders at this time, though they expect to seek similar authority in 2023. Provectus is focused on developing immunotherapy medicines utilizing its proprietary rose bengal sodium (RBS) for various diseases and has been recognized for its high purity RBS formulation.

Provectus presented promising results from its ongoing Phase 1b/2 study of PV-10 and Keytruda for treating Stage III cutaneous melanoma at Melanoma Bridge 2022. Highlights include a 50% complete response rate (3/6 patients) and an 83% overall response rate (5/6 patients). Rapid complete responses were observed within 15 to 27 weeks. The study reported an 83% progression-free survival rate and a 100% overall survival rate for complete responders after 18 to 36 months. The findings suggest significant potential for the combination therapy, with plans for a Phase 2/3 trial in 2023.

Provectus (OTCQB: PVCT) announced the presentation of data from its ongoing Phase 1b/2 study combining PV-10 immunotherapy with KEYTRUDA for Stage III cutaneous melanoma. This presentation will occur at Melanoma Bridge 2022 in Naples, Italy, from December 1-3, 2022. The accepted abstract, titled “Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in stage III cutaneous melanoma,” will be delivered as a video oral communication and poster.

Provectus (OTCQB: PVCT) announced that the World Health Organization's INN Expert Committee has selected "rose bengal sodium" as the official nonproprietary name for its active pharmaceutical ingredient. This designation follows a public consultation and signifies a step towards enhanced regulatory oversight. Provectus claims to be the first to produce pharmaceutical-grade RBS with nearly 100% purity, utilizing a patented commercial-scale synthesis process. The company views this milestone as crucial for advancing its clinical development and drug discovery programs.